Pfizer’s Vizimpro receives EMA approval recommendation for NSCLC treatment

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a significant boost to Pfizer's lung cancer drug, Vizimpro (dacomitinib), ... Read More